Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice

Autores de IIS La Fe

• Antonio Javier Sahuquillo Torralba

  Autor

• Blanca De Unamuno Bustos

  Autor

• Mercedes Rodríguez Serna

  Autor

• Emilio Monte Boquet

  Autor

• 

  Rafael Botella Estrada

  Autor

Grupos

• Dermatología y Regeneración Tisular

Abstract

Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in routine clinical practice is available. We aimed to assess treatment safety and persistence rates in patients on apremilast for different forms of plaque psoriasis. This observational retrospective study included 30 patients with psoriasis who were treated with apremilast between January 2016 and December 2017 in our hospital. Twelve patients had palmar-plantar psoriasis, 8 had plaque psoriasis mainly on the scalp, and 10 had plaque psoriasis in other locations. The probable period of treatment persistence in patients in the 50th percentile was 18.5 months according to survival analysis of the series overall. Our experience suggests that apremilast is effective and safe for treating palmar-plantar psoriasis and plaques at other locations but not for treating scalp psoriasis. Adverse effects that compromise treatment occur in nearly two-thirds of the patients. (C) 2020 Published by Elsevier Espana, S.L.U. on behalf of AEDV.

Keywords

• Apremilast; Clinical practice; Specific locations; Adverse effects